LOS ANGELES, Oct 19 (Reuters) - U.S. health regulators declined on Tuesday to approve a diabetes drug being developed by Amylin Pharmaceuticals Inc's (AMLN.O) and Eli Lilly and Co (LLY.N), citing the need for further studies, including the drug's effect on heart rate.
